Cadila Healthcare consolidated net jumps by 39% inQ1

Cadila Healthcare, a Rs 2850 crore Ahmedabad based pharma major, has posted satisfactory performance during the first quarter ended June 2009 on account of robust performance in the US. The company's consolidated net profit went up by 39.1 per cent to Rs 124.79 crore from Rs 90 crore in the corresponding period of last year. Its consolidated net sales also increased by 28.4 per cent to Rs 880.31 crore from Rs 685.71 crore. 

An overall 66 per cent growth in formulation exports was driven by growth in US Europe and the emerging markets. Its sales in US moved up 81 per cent to Rs 147.90 crore. The group launched mycophenolate mofetil tablets and capsules in May 2009. In Europe, the group registered growth of 39 per cent and posted sales of Rs 63.80 crore. Four new products were launched in the French generics market during the quarter. Exports to emerging markets grew by 86 per cent with sales of Rs 52.60 crore.